Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies

Giulia Giorgetti, Pamela Becherini, Elena Maroto-Martin, Daniela Fenoglio, Debora Soncini, Claudia Martinuzzi, Santina Bruzzone, Andrea Benzi, Aimable Nahimana, Chiara Rosa Maria Uras, Anaïs Schavgoulidze, Jessica Ng Fong, Roberto M. Lemoli, Nikhil C Munshi, Mariateresa Fulciniti, Michele Cea

Blood (2023) 142 (Supplement 1): 1951.

https://doi.org/10.1182/blood-2023-189439

Published: 2023

Journal Articles

The NAD + Metabolic Dependency Restriction Overcomes Drug-Resistance Phenotype of Multiple Myeloma CELLS

Debora Soncini, Pamela Becherini, Silvia Ravera, Claudia Martinuzzi, Alessio Nencioni, Santina Bruzzone, Francesco Piacente, Giulia Giorgetti, Francesco Ladisa, Michel A. Duchosal, Aimable Nahimana, Roberto M. Lemoli, Michele Cea

Blood (2023) 142 (Supplement 1): 6609.

https://doi.org/10.1182/blood-2023-189720

Published: 2023

Journal Articles

Regulation Of CLL Growth and Trafficking By The Enzymatic Functions Of CD38: Implications For Therapeutic Targeting

Tiziana Vaisitti, PhD, Valentina Audrito, Sara Serra, Giovanna Sociali, Antonella Zucchetto, Erika Tissino, Andrea Pagnani, Candida Vitale, MD, Marta Coscia, MD, PhD, Valter Gattei, Santina Bruzzone, Silvia Deaglio, MD, PhD

Blood (2013) 122 (21): 4112.

https://doi.org/10.1182/blood.V122.21.4112.4112

Published: 2013

Journal Articles

Catastrophic NAD + Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE.

Santina Bruzzone, Ph.D., Floriana Fruscione, Sara Morando, Alessandro Poggi, Anna Garuti, Martina Selmo, Tiziana Ferrando, Federica Benvenuto, Michele Cea, MD, Debora Soncini, Eva Moran, Ph.D., Ilaria Rocco, Gabriella Cirmena, Gabriele Zoppoli, MD, Alberto Ballestrero, MD, Ph.D., Bernard Sordat, Franco Patrone, Antonio Uccelli, Alessio Nencioni, MD, Ph.D.

Blood (2009) 114 (22): 4732.

https://doi.org/10.1182/blood.V114.22.4732.4732

Published: 2009

Journal Articles

Deacetylase Inhibitor Cocktails Provide Striking Synergistic Interactions in Human Leukemia Cells.

Michele Cea, MD, Antonia Cagnetta, Floriana Fruscione, Santina Bruzzone, Ph.D., Gabriele Zoppoli, MD, Anna Garuti, Eva Moran, Ph.D., Valentina Grillo, Fabio Ferrando, Salvatore Casciaro, Ivana Pierri, Marco Gobbi, MD, Alberto Ballestrero, MD, Ph.D., Franco Patrone, MD, Ph.D., Alessio Nencioni, MD, Ph.D.

Blood (2009) 114 (22): 4404.

https://doi.org/10.1182/blood.V114.22.4404.4404

Published: 2009

Journal Articles

Potent Synergistic Activity of the NAD+ Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.

Blood (2009) 114 (22): 2733.

https://doi.org/10.1182/blood.V114.22.2733.2733

Published: 2009

Journal Articles

APO866 activity in hematologic malignancies: a preclinical in vitro study

Michele Cea, Gabriele Zoppoli, Santina Bruzzone, Floriana Fruscione, Eva Moran, Anna Garuti, Ilaria Rocco, Gabriella Cirmena, Salvatore Casciaro, Francesca Olcese, Ivana Pierri, Antonia Cagnetta, Fabio Ferrando, Riccardo Ghio, Marco Gobbi, Alberto Ballestrero, Franco Patrone, Alessio Nencioni

Blood (2009) 113 (23): 6035–6037.

https://doi.org/10.1182/blood-2009-03-209213

Published: 2009

NARROW

Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies

The NAD + Metabolic Dependency Restriction Overcomes Drug-Resistance Phenotype of Multiple Myeloma CELLS

Regulation Of CLL Growth and Trafficking By The Enzymatic Functions Of CD38: Implications For Therapeutic Targeting

Catastrophic NAD + Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE.

Deacetylase Inhibitor Cocktails Provide Striking Synergistic Interactions in Human Leukemia Cells.

Potent Synergistic Activity of the NAD+ Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.

APO866 activity in hematologic malignancies: a preclinical in vitro study

Email alerts

ASH Publications

American Society of Hematology

Higher CD56 Expression on Multiple Myeloma Cells Increases CD38 Expression, Reduces Intracellular NAD+ Levels, and Enhances the Efficacy of Daratumumab-Based Treatment Strategies

The NAD + Metabolic Dependency Restriction Overcomes Drug-Resistance Phenotype of Multiple Myeloma CELLS

Regulation Of CLL Growth and Trafficking By The Enzymatic Functions Of CD38: Implications For Therapeutic Targeting

Catastrophic NAD + Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE.

Deacetylase Inhibitor Cocktails Provide Striking Synergistic Interactions in Human Leukemia Cells.

Potent Synergistic Activity of the NAD+ Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.

APO866 activity in hematologic malignancies: a preclinical in vitro study

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only